Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.
How this was made
The 30-second read
Why it matters
The key tradable elements are (1) incremental Oxford financing that extends runway, (2) FDA acceptance of the ozekibart BLA with an April 14, 2027 PDUFA goal date, and (3) planned clinical data timing for INBRX-106 (Q3 2026 PFS) and ozekibart Phase 1 CRC cohorts (interim results expected in Q1 2027).
Market read
This is a milestone-heavy biotech update combining financing, FDA process timing, and upcoming clinical readouts, which can reprice risk ahead of 2026-2027 catalysts.
What to watch
R&D and G&A increases plus net loss widening could keep valuation sensitive to future dilution risk, even with the PDUFA date and incremental funding.
Background
Inhibrx is a clinical-stage biopharmaceutical company with two ongoing clinical programs, ozekibart (INBRX-109) and INBRX-106.
Ticker impact
Inhibrx reported Q2 2026 results and disclosed a $325M Oxford loan amendment plus FDA BLA acceptance for ozekibart with a 4/14/2027 PDUFA date.
Moderate upside bias if investors view the Oxford incremental funding and the April 2027 PDUFA as de-risking; downside risk if cash burn and higher R&D and interest expense raise dilution or financing concerns.
The article provides multiple concrete catalysts (loan proceeds, FDA filing acceptance with PDUFA goal date, and planned data milestones) but lacks any new efficacy/safety datapoint, limiting conviction on direction.
Market effects
Adds another example of FDA BLA acceptance and milestone-driven capital planning in clinical-stage oncology biotech.
Limited, primarily affects US small-cap biotech sentiment and Nasdaq biotech complex.
Low; regulatory and financing details are company-specific.
Counterpoint
Loan amendment and higher interest expense may signal continued financing needs, and without new clinical efficacy data the market may fade the news quickly.
Key entities
- companyInhibrx Biosciences, Inc.
Reported Q2 2026 financial results and provided financing, FDA, and clinical milestone updates.
- lenderOxford Finance LLC
Provided an amended loan agreement with additional gross proceeds up to $325M.
- regulatorU.S. Food and Drug Administration (FDA)
Accepted the ozekibart BLA for filing and set a PDUFA goal date of April 14, 2027.
- drug_programINBRX-109 (ozekibart)
BLA accepted for conventional chondrosarcoma; CRC first-line registrational trial and accelerated pathway discussed with FDA.
- drug_programINBRX-106
Planned Q3 2026 announcement of PFS data in HNSCC with pembrolizumab.
